Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > thrombosis drugs market
Get a free sample of Thrombosis Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Thrombosis Drugs Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The thrombosis drugs industry is marked by fierce competition, involving major multinational, smaller and mid-sized companies. A central market strategy involves the continuous innovation and introduction of advanced products, leveraging diverse technologies. This approach aims to gain a competitive edge by meeting medical needs and capturing market share. Overall, the pursuit of innovation remains a cornerstone strategy in the highly competitive thrombosis drugs industry.
Some of the eminent market participants operating in the thrombosis drugs industry include:
Thrombosis drugs market size was USD 31.2 billion in 2023 and is expected to register 8.2% CAGR from 2024-2032 owing to the ongoing advancements in drug development, an increase in the prevalence of thrombotic disorders, and growing geriatric population worldwide.
The anticoagulants segment recorded USD 17.8 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to increased awareness among healthcare professionals and patients about the importance of appropriate anticoagulant therapy.
North America thrombosis drugs industry recorded USD 13.4 billion in 2023 due to the rising pharmaceutical research and development, with numerous biopharmaceutical companies and academic institutions engaged in thrombosis drug discovery and clinical trials in the region.
Baxter International Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., and Sanofi, are some of the major thrombosis drugs companies worldwide.